Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
800 participants
OBSERVATIONAL
2015-09-11
2029-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Treatment of PJI combines surgery and prolonged antibiotic therapy. In some patients with a high operative risk prolonged suppressive antibiotic therapy can be used.
Lack of large prospective studies motivated the conception of this cohort with a long term follow up, regardless to PJI management procedures.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Bacteriological Setting Before Prosthesis Implantation With One Stage Surgery in Prosthetic Joint Infection
NCT02806063
Quality of Life Assessment in Patients Undergoing Prolonged Suppressive Antibiotherapy for Prosthetic Joint Infection.
NCT02805803
Physiopathology of Prosthetic Joint Infections
NCT05551572
European Prosthetic Joint Infection Cohort Study- Hip, Knee and Shoulder Prosthetic Joint Infection
NCT02424903
Dosing of Antibiotics During Reimplantation of Infected Knee and Hip Prostheses
NCT02860767
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Population
* all patients who consented to participate in the study with PJI treated with:
* debridement-synovectomy for acute infection
* with one-stage, two-stage exchange arthroplasty for chronic infection
* other procedures (complete removal of the prosthesis) and antibiotic therapy
* patients (non-operated or operated) receiving prolonged suppressive antibiotic therapy
Outcome:
* Follow-up at least 2 years
* Events monitored: reinfection including relapse and new infection, joint revision for mechanical failure, PJI related or non-related death Study duration: 10 years. Recruitment period: 4 years. Maximal duration of data collection: 6 years. Investigator center: monocenter study. Mean patient inclusion per year: 100 patients per year.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* According to musculoskeletal infection society definition: PJI is present when one of the major criteria exists or four out of six minor criteria.
Major Criteria:
* Two positive periprosthetic cultures with phenotypically identical organisms, OR
* A sinus tract communicating with the joint, OR
Minor Criteria:
* Elevated serum C-reactive protein (CRP) AND erythrocyte sedimentation rate (ESR)
* Elevated synovial fluid white blood cell (WBC)
* Elevated synovial fluid polymorphonuclear neutrophil percentage (PMN%)
* The presence of pus in the joint without known cause
* Positive histological analysis of periprosthetic tissue
* A single positive culture
Or a PJI which meets the following three criteria:
* Medical story suggesting prosthetic joint infection.
* The presence of pain either with or without swelling for more than 3 months unrelated to a mechanical cause.
* Germ identification in a single sample of fluid aspiration or tissue culture.
* Or microbial growth in prosthesis sonication fluid culture greater than 50CFU/ml.
Exclusion Criteria
* Patient lawfully deprived of his liberty.
* Patient not insured under social security scheme.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Groupe Hospitalier Diaconesses Croix Saint-Simon
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr Valerie ZELLER
infectious diseases specialist
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
VALERIE ZELLER, Doctorate
Role: PRINCIPAL_INVESTIGATOR
Groupe Hospitalier Diaconesses Croix Saint-Simon
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Groupe Hospitalier Diaconesses Croix Saint Simon
Paris, Île-de-France Region, France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ID RCB: 2014-A01100-47
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.